TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.69 CNY | -1.07% |
|
0.00% | -12.97% |
| 03-01 | Tianjin Chase Sun Pharmaceutical's 2023 Profit Slides 15% on Weak Revenue | MT |
| 02-29 | Tianjin Chase Sun Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Sales per Business
| CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Traditional Chinese Medicine Formula Granules and Decoction Pieces
47.9
%
| 3,360 | 50.5 % | 2,923 | 47.9 % | -12.99% |
Blood-essential Injection
13.9
%
| 817 | 12.3 % | 851 | 13.9 % | +4.23% |
Smart Pharmaceutical Supply Chain
11.7
%
| 588 | 8.8 % | 715 | 11.7 % | +21.66% |
Medical Device
6.3
%
| 674 | 10.1 % | 383 | 6.3 % | -43.12% |
Excipients
5.6
%
| 361 | 5.4 % | 344 | 5.6 % | -4.80% |
Low Molecular Weight Heparin Calcium Injection
4.7
%
| 305 | 4.6 % | 287 | 4.7 % | -5.82% |
Moxifloxacin Hydrochloride Sodium Chloride Injection
3.1
%
| 165 | 2.5 % | 189 | 3.1 % | +14.49% |
Other Products
3.1
%
| 233 | 3.5 % | 189 | 3.1 % | -18.85% |
API
2.6
%
| 147 | 2.2 % | 156 | 2.6 % | +6.07% |
Enoxaparin Sodium Injection
1.2
%
| - | - | 71 | 1.2 % | - |
Sales per region
| CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
China
93.5
%
| 5,923 | 89.1 % | 5,167 | 93.5 % | -12.77% |
Overseas
6.5
%
| 727 | 10.9 % | 361 | 6.5 % | -50.29% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Dan Zheng
CEO | Chief Executive Officer | 60 | - |
Wu Jun Lan
DFI | Director of Finance/CFO | 49 | - |
Wu Sun
BRD | Director/Board Member | 55 | - |
Dan Liang
BRD | Director/Board Member | 43 | 15/04/13 |
Rui Qiang Chen
HRO | Human Resources Officer | 47 | 24/06/15 |
Qin Pan
PRN | Corporate Officer/Principal | 54 | 25/04/19 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Qing Yao
FOU | Founder | 59 | 22/09/96 |
Li Li
BRD | Director/Board Member | 63 | 17/11/20 |
Dan Zheng
CEO | Chief Executive Officer | 60 | - |
Wu Jun Lan
DFI | Director of Finance/CFO | 49 | - |
Da Wei Miao
BRD | Director/Board Member | 69 | 07/05/07 |
Dan Liang
BRD | Director/Board Member | 43 | 15/04/13 |
Tao Gong
BRD | Director/Board Member | 55 | 15/01/20 |
Sheng Tian Wang
BRD | Director/Board Member | 73 | 27/12/17 |
Xu Feng Pu
BRD | Director/Board Member | 61 | 15/01/20 |
Wu Sun
BRD | Director/Board Member | 55 | - |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 3,004,154,837 | 826,252,275 ( 27.50 %) | 0 | 27.50 % |
Company contact information
Tianjin Chase Sun Pharmaceutical Co., Ltd.
B01 Building Entrepreneurship Headquarters Base
301700, Tianjin
+86 22 5962 3160
http://www.chasesun.cn
Sector
Sales per Business
Sales per region
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.69
CNY
Average target price
4
CNY
Spread / Average Target
+8.40%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.97% | 1.53B | |
| +35.04% | 5.92B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| -7.89% | 1.68B | |
| +0.09% | 1.65B | |
| +33.40% | 1.38B |
- Stock Market
- Equities
- 300026 Stock
- Company Tianjin Chase Sun Pharmaceutical Co.,Ltd
